Cardiome Pharma Corporation (NASDAQ: CRME) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Cardiome Pharma Corporation and Biogen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiome Pharma Corporation 0 1 4 0 2.80
Biogen 0 12 11 1 2.54

Cardiome Pharma Corporation currently has a consensus price target of $6.56, indicating a potential upside of 202.42%. Biogen has a consensus price target of $329.27, indicating a potential upside of 3.40%. Given Cardiome Pharma Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Cardiome Pharma Corporation is more favorable than Biogen.

Profitability

This table compares Cardiome Pharma Corporation and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiome Pharma Corporation -110.95% -78.51% -38.30%
Biogen 28.10% 37.42% 20.12%

Volatility & Risk

Cardiome Pharma Corporation has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cardiome Pharma Corporation and Biogen’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cardiome Pharma Corporation $23.21 million 3.16 -$17.41 million ($0.83) -2.61
Biogen $11.72 billion 5.75 $6.42 billion $15.23 20.91

Biogen has higher revenue and earnings than Cardiome Pharma Corporation. Cardiome Pharma Corporation is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

55.1% of Cardiome Pharma Corporation shares are held by institutional investors. Comparatively, 87.7% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Biogen beats Cardiome Pharma Corporation on 11 of the 14 factors compared between the two stocks.

Cardiome Pharma Corporation Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Biogen Company Profile

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.